CRIS Current Research Information System

Hallek M, F.K., International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. THE LANCET, 376, 1164-1174 [10.1016/S0140-6736(10)61381-5].

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

ZINZANI, PIER LUIGI;
2010
2010
THE LANCET
Hallek M, F.K., International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. THE LANCET, 376, 1164-1174 [10.1016/S0140-6736(10)61381-5].
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL,...espandi
1.01 Articolo in rivista
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/99853
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 604
  • Scopus 1658
  • ???jsp.display-item.citation.isi??? 1545
social impact